A set of best-practice recommendations focuses on maintaining plasma sample quality for blood-based amyloid pathology testing, specifically for the pTau 217/β-Amyloid 1-42 plasma ratio test. The guidance addresses collection, processing, storage, and preparation steps designed to improve reliability of results. For laboratories running blood-based biomarkers, sample handling can influence analyte stability and assay performance, meaning pre-analytical variables are often as important as the downstream measurement platform. The recommendations target how to standardize workflows so test outputs better reflect underlying amyloid pathology rather than variability introduced before testing. The note’s emphasis on pre-analytical rigor aligns with broader clinical interest in blood biomarkers for amyloid detection, including in patient selection and monitoring contexts where reproducibility is critical. As clinical adoption of plasma amyloid assays grows, practical workflow controls like these help support consistent implementation across sites and study settings.